ClinicalTrials.gg
CompletedNCT00758069Updated May 5, 2017Results posted

Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)

A Phase 2 interventional study of sitagliptin phosphate and Comparator: Placebo in Diabetes Mellitus, Non-Insulin-Dependent, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 69 Years. Per ClinicalTrials.gov, last updated 2017-05-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 2 months after the study started (first participant enrolled Jul 2005, registered Sep 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
20 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
109th of 197
80 · median 102
Started
2005
with 3 others
Phase 2
10 of 198
none open now
Registered
55th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 109th largest by enrollment of the 197 interventional ones that give a count, is one of 4 that started in 2005, is one of 10 in phase 2, and was the 55th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A clinical study determines the safety and efficacy of sitagliptin (MK0431) in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy

03

Conditions studied

  • Diabetes Mellitus, Non-Insulin-Dependent
04

Who can participate

Ages eligible
20 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients Have Type 2 Diabetes Mellitus On Diet/Exercise Therapy

Exclusion criteria

Exclusion Criteria:

  • Patients Have Type 1 Diabetes Mellitus
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Placebo comparator
    1

    Placebo

    Drug: Comparator: Placebo

  • Experimental
    2

    Sitagliptin 100 mg

    Drug: sitagliptin phosphate

  • Experimental
    3

    Sitagliptin 50 mg

    Drug: Comparator: Sitagliptin

Interventions

  • 100 mg once daily (QD), taken orally for 4 weeks

    Also known as: MK0431

  • DrugComparator: Placebo

    Placebo tablet, QD, taken orally for 4 weeks

  • 50 mg twice daily (BID), taken orally for 4 weeks

    Also known as: MK0431

06

What researchers measure

Primary outcomes

  1. Change From Baseline in 24-hour Weighted Mean Plasma Glucose

    Change from baseline at Week 4 is defined as 24-hour weighted mean glucose (24hr-WMG) at Week 4 minus 24hr-WMG at Week 0.

    Time frame: Baseline and Week 4

Secondary outcomes

  1. Change From Baseline in Plasma Glucose

    Change from baseline at Week 4 is defined as fasting plasma glucose at Week 4 minus fasting plasma glucose at Week 0.

    Time frame: Baseline and Week 4

07

Results

Posted Sep 25, 2009
Limitations and caveats
Reported overdoses, regardless of association with reported adverse events, were considered as serious adverse events in this study. The patients for whom the event of overdose was reported had no concomitant AEs with the overdose.

Participant flow

Phase II. First patient in: 31 July 2005. Last patient, last visit: 13 February 2006. The study was conducted at 8 centers in Japan.

Participant flow — Overall Study
MilestoneSitagliptin 100 mg QDSitagliptin 50 mg BIDPlacebo
Started272528
Completed262527
Not completed101
Withdrew: Lack of efficacy001
Withdrew: Incorrect study drug100

Outcome measures

PrimaryChange From Baseline in 24-hour Weighted Mean Plasma Glucose

Change from baseline at Week 4 is defined as 24-hour weighted mean glucose (24hr-WMG) at Week 4 minus 24hr-WMG at Week 0.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mg/dL
Change From Baseline in 24-hour Weighted Mean Plasma Glucose
mg/dLSitagliptin 100 mg QDSitagliptin 50 mg BIDPlacebo
Change From Baseline in 24-hour Weighted Mean Plasma Glucose-34.9 (-40.9 to 28.9)-28.6 (-34.7 to 22.4)-9.0 (-14.8 to -3.2)
Statistical analysis
  • Sitagliptin 100 mg QD vs Placebo · ANCOVA · p = <0.001 (No multiplicity adjustment among the pairwise comparisons of sitagliptin against placebo) · Least-squares mean difference: -25.9 · 95% CI -34.2 to -17.5ANCOVA model with terms of treatment as a factor and baseline value as a covariate was used to estimate difference of two groups and its 95% confidence interval
  • Sitagliptin 50 mg BID vs Placebo · ANCOVA · p = <0.001 (No multiplicity adjustment among the pairwise comparisons of sitagliptin against placebo) · Least-squares mean difference: -19.5 · 95% CI -28.0 to -11.1ANCOVA model with terms of treatment as a factor and baseline value as a covariate was used to estimate difference of two groups and its 95% confidence interval
SecondaryChange From Baseline in Plasma Glucose

Change from baseline at Week 4 is defined as fasting plasma glucose at Week 4 minus fasting plasma glucose at Week 0.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mg/dL
Change From Baseline in Plasma Glucose
mg/dLSitagliptin 100 mg QDSitagliptin 50 mg BIDPlacebo
Change From Baseline in Plasma Glucose-22.3 (-27.7 to 17.0)-16.0 (-21.4 to 10.6)-3.1 (-8.2 to 2.0)
Statistical analysis
  • Sitagliptin 100 mg QD vs Placebo · ANCOVA · p = <0.001 (No multiplicity adjustment among the pairwise comparisons of sitagliptin against placebo) · Least-squares mean difference: -19.3 · 95% CI -26.6 to -11.9ANCOVA model with terms of treatment as a factor and baseline value as a covariate was used to estimate difference of two groups and its 95% confidence interval
  • Sitagliptin 50 mg BID vs Placebo · ANCOVA · p = <0.001 (No multiplicity adjustment among the pairwise comparisons of sitagliptin against placebo) · Least-squares mean difference: -12.9 · 95% CI -20.4 to -5.4ANCOVA model with terms of treatment as a factor and baseline value as a covariate was used to estimate difference of two groups and its 95% confidence interval

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 100 mg QD———
Sitagliptin 50 mg BID———
Placebo———
Most frequent serious events
Most frequent serious events
EventSitagliptin 100 mg QDSitagliptin 50 mg BIDPlacebo
OverdoseInjury, poisoning and procedural complications1/272/250/28
Most frequent other events
Most frequent other events
EventSitagliptin 100 mg QDSitagliptin 50 mg BIDPlacebo
NasopharyngitisInfections and infestations1/271/252/28

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sitagliptin 100 mg QDSitagliptin 50 mg BIDPlaceboTotal
Mean54.2 ± 8.956.1 ± 8.953.6 ± 10.354.6 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin 100 mg QDSitagliptin 50 mg BIDPlaceboTotal
Female107825
Male17182055
24-hour weighted mean plasma glucose (24hr-WMG)
24-hour weighted mean plasma glucose (24hr-WMG)(mg/dL)Sitagliptin 100 mg QDSitagliptin 50 mg BIDPlaceboTotal
Mean195.0 ± 55.6188.9 ± 46.6195.4 ± 46.2193.2 ± 49.1
Fasting Plasma Glucose (FPG)
Fasting Plasma Glucose (FPG)(mg/dL)Sitagliptin 100 mg QDSitagliptin 50 mg BIDPlaceboTotal
Mean158.6 ± 41.0156.4 ± 41.3164.1 ± 36.9159.9 ± 39.3
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Nonaka K, Tsubouchi H, Okuyama K, Fukao Y, Johnson-Levonas AO, Amatruda JM. Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus. Horm Metab Res. 2009 Mar;41(3):232-7. doi: 10.1055/s-0028-1100413. Epub 2009 Feb 27. PubMed 19253204 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2005 to primary completion in Feb 2006, 7 months.

Results were first posted in Sep 2009, 3 years 7 months after primary completion.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 7 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2008
First posted
Sep 23, 2008
StartActual
Jul 3, 2005
Primary completionActual
Feb 13, 2006
CompletionActual
Feb 13, 2006
Results first posted
Sep 25, 2009
Last update
May 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00758069
Responsible party
Sponsor
First posted
Sep 23, 2008
Start date
Jul 3, 2005
Primary completion
Feb 13, 2006
Completion
Feb 13, 2006
Results posted
Sep 25, 2009
Last update
May 5, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion